NCT05194072: A Study of SGN-B7H4V in Advanced Solid Tumors

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease; Patients with prior exposure to an MMAE-containing agent (e.g. Enfortumab vedotin) or an agent targeting B7-H4

Comments are closed.

Up ↑